Friday, January 24, 2025

Swiss Strategy A.G. to Launch Switzerland’s First Smoke-Free Cigarette – NicStic

 

Swiss Strategy A.G. to Launch Switzerland’s First Smoke-Free Cigarette – NicStic


featured Image
January 25, 2025 ( PR Submission Site ) –

Zurich, Switzerland – Swiss Strategy Aktiengesellschaft proudly announces the introduction of Switzerland’s first smoke-free cigarette, NicStic. Following an evaluation by the Swiss Medicines Institute, Swissmedic, the product has been determined not to fall under the scope of medicines law. This milestone paves the way for NicStic to be produced and sold in the Swiss market.  

NicStic is an innovative product designed to provide nicotine in a cigarette-like manner without exposing users or bystanders to harmful tobacco smoke. As global smoking bans and restrictions become increasingly prevalent, NicStic offers a revolutionary solution for nicotine-dependent smokers who face significant physical and psychological challenges due to these regulations.  

With product development completed, series production is slated to begin this fall. The product has already garnered substantial interest, with widespread anticipation for its launch both in Switzerland and internationally.  

To support the global market rollout, Swiss Strategy A.G. is actively engaging with private and institutional investors, alongside potential licensees across Europe and overseas.  

“We are thrilled to introduce this groundbreaking product to address the needs of nicotine-dependent smokers worldwide,” said Marina Krueger, Ph.D., Chief Medical Officer of Swiss Strategy Aktiengesellschaft. “NicStic represents a safe, innovative, and practical alternative to conventional smoking, aligning with evolving health and regulatory landscapes.” 

About Swiss Strategy A.G.

Swiss Strategy A.G. is a Swiss marketing firm dedicated to promoting science-based innovations that benefit the economy and society. The company facilitates partnerships between visionary scientists and the Swiss market, bringing patented inventions and inspiring solutions to life. Swiss Strategy A.G. champions Swiss start-ups and innovative products that shape the future.  

† These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.  

For more information about NicStic, please visit: https://demo6429d4d7979f7.yolasitebuilder.loopia.com 

Investor Relations:

Marina Krueger, Ph.D.  

Chief Medical Officer  

Swiss Strategy Aktiengesellschaft  

Schützenmattstrasse 71  

CH-8180 Bülach, Switzerland  

Tel: +41 79 123 57-84  

Email: news@nicstic.eml.monster  

Blog: https://nicsticag.blogspot.com  

Photo Caption: Thomas Schroepfer presenting NicStic on WSVN-TV South Florida’s News Station.  

SOURCE: Swiss Strategy A.G.

YouTube Link: https://www.youtube.com/watch?v=bEyHr–_UJI

The financial future of NicStic appears promising, driven by its unique positioning as a smoke-free cigarette in a global market increasingly focused on health-conscious solutions and stricter smoking regulations. With production slated to begin soon and significant interest from investors and licensees across Europe and overseas, NicStic is poised to capitalize on a growing demand for alternatives to traditional smoking. Its innovative approach not only broadens the customer base but also opens opportunities for strategic partnerships and licensing agreements. As awareness and adoption increase, NicStic has the potential to establish a strong foothold in the multi-billion-dollar nicotine alternatives market, paving the way for sustained growth and profitability.


Summary

Swiss Strategy A.G. has announced the launch of Switzerland's first smoke-free cigarette, NicStic, an innovative product providing nicotine in a cigarette-like experience without harmful tobacco smoke. Approved by the Swiss Medicines Institute (Swissmedic) for market entry, NicStic addresses the growing challenges faced by nicotine-dependent smokers amid increasing smoking bans worldwide. With product development completed and production beginning this fall, the company is engaging with investors and licensees for a global rollout. Chief Medical Officer Marina Krueger, Ph.D., highlights NicStic as a safe, practical alternative for smokers, marking a significant step in promoting health-conscious solutions.


Leave a Reply

Logged in as Marina Krueger. Edit your profile. Log out? Required fields are marked *

 

“Jewish Penicillin” Cough Drop Inventor Calls Out Progresso Soup for Launching “Knock-Off” Product

 

“Jewish Penicillin” Cough Drop Inventor Calls Out Progresso Soup for Launching “Knock-Off” Product


featured Image
January 24, 2025 ( PR Submission Site ) –

NEW YORK — Richard H. Davis, President and CEO of Nautilus Biotech Corporation, is calling out Progresso Soup for what he describes as a blatant “knock-off” of his company’s innovative product, JEWISH PENICILLIN™ Cough Drops. Davis launched the patent-pending cough drops—combining the cold-fighting power of chicken soup and menthol—on November 24, 2022. However, Progresso has recently announced a similar product, limited-edition chicken soup-flavored “Soup Drops,” dated for release on January 16, 2025.  

Progresso’s press release promotes their product as “a fun, savory candy Soup Drop” inspired by their Chicken Noodle Soup. MC Comings, VP and Business Unit Director for Progresso at General Mills, stated, “We took the beloved flavors of our Progresso Chicken Noodle Soup and packed them into a fun, savory candy for a totally new way to enjoy the taste you love whenever and wherever you want.”  

Davis, however, sees the resemblance as more than coincidental. “Progresso’s product announcement comes suspiciously close to our innovative launch,” Davis said. “JEWISH PENICILLIN™ Cough Drops provide a unique, fast-acting solution for cough and sore throat relief by combining the therapeutic effects of chicken soup and menthol. It’s disappointing to see a household brand like Progresso mimic our design and concept.”  

JEWISH PENICILLIN™ Cough Drops were unveiled over the High Holy Days and Shabbat שַׁבָּת שׁוּבָה, aligning with a longstanding cultural recognition of chicken soup as a natural remedy. The cough drops have been widely lauded for providing relief from upper respiratory symptoms, a tradition dating back to the 12th century when the Jewish physician Moshe ben Maimonides extolled chicken soup’s medicinal benefits.  

The Legacy of Chicken Soup as Medicine 

“Your Jewish grandmother may have unknowingly tapped into a scientifically supported remedy for colds with her chicken soup,” Davis said. “Modern research backs up what we’ve known for centuries—chicken soup contains anti-inflammatory properties that may ease symptoms of upper respiratory tract infections.”  

Davis referenced a study published in the CHEST journal that highlighted chicken soup’s medicinal potential. However, he emphasized that Progresso’s actions dilute the originality and authenticity behind his product, which has been carefully crafted to deliver both taste and therapeutic effects.  

Taking Action 

Consumers and industry professionals are encouraged to reach out to Progresso Soup to express their concerns about its copycat practices. Contact:  

Ali Barzyk 

Email: Ali.Barzyk@edelman.com  

For more information about JEWISH PENICILLIN™ Cough Drops and their innovative health benefits, visit https://jewishpenicillincoughdrops.blogspot.com.  

About Nautilus Biotech Corporation

Nautilus Biotech Corporation is committed to developing cutting-edge, scientifically backed remedies for common health challenges. The company’s flagship product, JEWISH PENICILLIN™ Cough Drops, combines tradition and innovation to provide fast-acting relief for coughs and sore throats. +1 ‪(212) 347-0550‬. 

Listen to the Full Statement Stream of this press release on Spotify: Spotify Link https://open.spotify.com/episode/7Ck9GyoFnX6h5B0pXs9SPw   

Chicken soup: The story of “Jewish penicillin”

https://www.youtube.com/watch?v=uayYXI_yg3w&t=6s

 


Summary

Nautilus Biotech Corporation, led by CEO Richard H. Davis, has accused Progresso Soup of releasing a "knock-off" product with their limited-edition chicken soup-flavored "Soup Drops," closely resembling the innovative JEWISH PENICILLIN™ Cough Drops launched in November 2022. Combining the cold-fighting properties of chicken soup and menthol, the JEWISH PENICILLIN™ Cough Drops provide fast relief for coughs and sore throats while drawing on the centuries-old tradition of chicken soup as a remedy. Davis highlights the originality and scientific backing behind his patent-pending product and urges Progresso to address these concerns, while inviting consumers to recognize the authenticity of Nautilus’s creation.


Leave a Reply

Logged in as Marina Krueger. Edit your profile. Log out? Required fields are marked *

 

Swiss Strategy A.G. to Launch Switzerland’s First Smoke-Free Cigarette – NicStic

  Contact us Journalists Log Out About Us Submit Press Release Submission Guidelines Blog Swiss Strategy A.G. to Launch Switzerland’s First ...